Taysha Gene Therapies, Inc.

US$4.33As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TSHAHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (23.60%)
Div yield —
ROE (47.05%)
Biotechnology
Beta (5Y) 1.31
PE TTM —
TSR TTM (12.70%)
Mkt cap US$1.411B
ROIC (25.44%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.22
20.54%
(69.96%)
Hold 4|4|6|1|6
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.07
0.08
0.07
0.08
37.00%
28.27%
12.24%
13.97%
Revenue$M
78.28
76.09
75.23
73.09
(2.63%)
(7.02%)
(6.67%)
(9.03%)
Peers (US$1.411B)
Cap (US$)
PE
1.389B
6.637x
Capital
TTM
5Y
10Y
Leveragex
1.642
0.357
0.321
EBIT/Intx
0.419
0.315
0.329
Own earn%
(13.85)
6.16
11.75
Sh yield%
31.36
27.19
24.13
Owners
Insiders/Inst%
8.34
56.32
Short interest%
5.37
SBC / revenue%
5.87
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
9–13
$1 testx
—
Incr. ROIC%
26